SBIR Phase I: Novel Advanced Nematicides with Improved Efficacy and Safety

SBIR 第一阶段：具有更高功效和安全性的新型先进杀线虫剂

• 批准号: 0944853
• 负责人: Urszula Slomczynska
• 金额: $ 15万
• 依托单位: Divergence, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0944853&HistoricalAwards=false
• 关键词: SBIR; Phase; Novel; Advanced; Nematicides

This SBIR Phase I project will develop novel nematicides using proprietary chemical design and screening methods. The project will first design, prioritize, and synthesize a set of entirely novel molecules. The project will then evaluate compounds for activity in multiple biological assays with parasitic nematodes and plants. Promising scaffolds will be prioritized for further development in Phase II including assessment of toxicity, manufacturing cost, and additional synthetic opportunities.The broader/commercial impact of the project will be to protect crops against nematodes which result in significant benefit to growers and the environment. The potential value to Divergence is very large, with the current nematicide market of $1 billion under representing the actual value that could be generated. REsulting effective nematicides with superior safety to current prodicts will be of immediate benefit to growers, consumers, and the environment.

该 SBIR 第一阶段项目将使用专有的化学设计和筛选方法开发新型杀线虫剂。 该项目将首先设计、优先排序并合成一组全新的分子。 然后，该项目将评估化合物在寄生线虫和植物的多种生物测定中的活性。 有前景的支架将优先在第二阶段进行进一步开发，包括毒性评估、制造成本和额外的合成机会。该项目更广泛/商业的影响将是保护作物免受线虫侵害，这将为种植者和环境带来重大利益。 Divergence 的潜在价值非常大，目前杀线虫剂市场为 10 亿美元，低于可能产生的实际价值。 由此产生的有效杀线虫剂，其安全性优于现有产品，将为种植者、消费者和环境带来直接利益。